Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: 5-Year Outcomes of the Randomized BIOFLOW-II Trial.
Lefèvre T, Haude M, Neumann FJ, Stangl K, Skurk C, Slagboom T, Sabaté M, Goicolea J, Barragan P, Cook S, Macia JC, Windecker S. Lefèvre T, et al. Among authors: haude m. JACC Cardiovasc Interv. 2018 May 28;11(10):995-1002. doi: 10.1016/j.jcin.2018.04.014. JACC Cardiovasc Interv. 2018. PMID: 29798778 Free article. Clinical Trial.
Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.
Windecker S, Haude M, Neumann FJ, Stangl K, Witzenbichler B, Slagboom T, Sabaté M, Goicolea J, Barragan P, Cook S, Piot C, Richardt G, Merkely B, Schneider H, Bilger J, Erne P, Waksman R, Zaugg S, Jüni P, Lefèvre T. Windecker S, et al. Among authors: haude m. Circ Cardiovasc Interv. 2015 Feb;8(2):e001441. doi: 10.1161/CIRCINTERVENTIONS.114.001441. Circ Cardiovasc Interv. 2015. PMID: 25634905 Clinical Trial.
The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
Haude M, Lee SW, Worthley SG, Silber S, Verheye S, Erbs S, Rosli MA, Botelho R, Meredith I, Sim KH, Stella PR, Tan HC, Whitbourn R, Thambar S, Abizaid A, Koh TH, Den Heijer P, Parise H, Cristea E, Maehara A, Mehran R. Haude M, et al. JACC Cardiovasc Interv. 2013 Apr;6(4):334-43. doi: 10.1016/j.jcin.2012.10.018. Epub 2013 Mar 20. JACC Cardiovasc Interv. 2013. PMID: 23523459 Free article. Clinical Trial.
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrié D, Piek JJ, Van Boven AJ, Dominici M, Dudek D, McClean D, Helqvist S, Haude M, Reith S, de Sousa Almeida M, Campo G, Iñiguez A, Sabaté M, Windecker S, Onuma Y. Serruys PW, et al. Among authors: haude m. Lancet. 2016 Nov 19;388(10059):2479-2491. doi: 10.1016/S0140-6736(16)32050-5. Epub 2016 Oct 30. Lancet. 2016. PMID: 27806897 Clinical Trial.
Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial).
Chevalier B, Cequier A, Dudek D, Haude M, Carrie D, Sabaté M, Windecker S, Reith S, de Sousa Almeida M, Campo G, Iñiguez A, Onuma Y, Serruys PW. Chevalier B, et al. Among authors: haude m. EuroIntervention. 2018 Jan 20;13(13):1561-1564. doi: 10.4244/EIJ-D-17-00873. EuroIntervention. 2018. PMID: 29094677 Free article. Clinical Trial. No abstract available.
Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.
Haude M, Ince H, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Neumann FJ, Eeckhout E, Garcia-Garcia HM, Waksman R. Haude M, et al. EuroIntervention. 2020 Feb 7;15(15):e1375-e1382. doi: 10.4244/EIJ-D-18-01000. EuroIntervention. 2020. PMID: 30803936 Free article. Clinical Trial.
Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II-III and BIOFLOW II trials.
Hideo-Kajita A, Garcia-Garcia HM, Kolm P, Azizi V, Ozaki Y, Dan K, Ince H, Kische S, Abizaid A, Töelg R, Lemos PA, Van Mieghem NM, Verheye S, von Birgelen C, Christiansen EH, Wijns W, Lefèvre T, Windecker S, Waksman R, Haude M; BIOFLOW-II, BIOSOLVE-II and BIOSOLVE-III investigators. Hideo-Kajita A, et al. Among authors: haude m. Int J Cardiol. 2020 Feb 1;300:60-65. doi: 10.1016/j.ijcard.2019.11.003. Epub 2019 Nov 6. Int J Cardiol. 2020. PMID: 31718825 Clinical Trial.
Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years.
Haude M, Toelg R, Lemos PA, Christiansen EH, Abizaid A, von Birgelen C, Neumann FJ, Wijns W, Ince H, Kaiser C, Lim ST, Escaned J, Eeckhout E, Garcia-Garcia HM, Waksman R. Haude M, et al. Cardiovasc Revasc Med. 2022 May;38:106-110. doi: 10.1016/j.carrev.2021.07.017. Epub 2021 Jul 22. Cardiovasc Revasc Med. 2022. PMID: 34364807
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial.
Gragnano F, Zwahlen M, Vranckx P, Heg D, Schmidlin K, Hamm C, Steg PG, Gargiulo G, McFadden EP, Onuma Y, Chichareon P, Benit E, Möllmann H, Janssens L, Leonardi S, Zurakowski A, Arrivi A, Van Geuns RJ, Huber K, Slagboom T, Calabrò P, Serruys PW, Jüni P, Valgimigli M, Windecker S; GLOBAL LEADERS Investigators [Link]. Gragnano F, et al. J Am Heart Assoc. 2022 May 17;11(10):e024291. doi: 10.1161/JAHA.121.024291. Epub 2022 Mar 1. J Am Heart Assoc. 2022. PMID: 35229616 Free PMC article. Clinical Trial.
395 results